19 research outputs found

    Real-World Treatment Patterns and Outcomes among Elderly Acute Myeloid Leukemia Patients in the United States

    Get PDF
    Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older. Using the linked SEER-Medicare database, we conducted a retrospective cohort analysis to examine patient characteristics, treatment patterns, and survival among the elderly AML patients in routine clinical practice. Out of 29,857 patients with AML in the database, 8336 were eligible for inclusion in the study. The inclusion criteria included a diagnosis with first primary AML between January 1, 2000 and December 31, 2009, >66 years of age, and continuous enrollment in Medicare Parts A and B in the year before diagnosis. Forty percent (N = 3327) of the cohort received chemotherapy within 3 months after diagnosis. The multivariable overall survival analyses showed a lower risk of death among those receiving intensive and hypomethylating agent therapies compared with no therapy. Among the younger cohort, a significant lower mortality was also noted with receipt of allogeneic hematopoietic stem cell transplantation. Over the past decade, about 60% of the elderly AML patients remain untreated in routine clinical practice. Use of antileukemic therapy was associated with a significant survival benefit and provides further support that age alone should not deter the use of guideline-recommended therapies particularly because of the high disparities in outcomes between treatment receipt and palliative care in this elderly cohort

    Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort

    Get PDF
    Experience (POSSIBLE US) were used to assess the prevalence of risk factors (RFs) and on-study fracture. RFs assessed at study entry were age >70 years; fracture since age 50; minimum T-score (hip/spine) ≤ −2.5 at diagnosis; body mass index <18.5 kg/m 2 ; rheumatoid arthritis; parental history of hip fracture; current smoking; and recent oral glucocorticoid use. Data were collected with semiannual self-administered questionnaires. Results were stratified by physician-reported osteoporosis/osteopenia diagnosis. Low T-score and age >70 years were the most common RFs in the osteoporosis group, and age >70 years and prior fracture were the most common risk factors in the osteopenia group. Multiple RFs were more common than a single RF in osteoporotic women (54.2% versus 34.6%; < 0.0001) but not osteopenic women (13.8% versus 33.6%; < 0.0001). Women with multiple RFs had more on-study osteoporosis-related fractures than women with a single RF (osteoporosis group: 9.9% versus 6.2%; = 0.0092; osteopenia group: 11.2% versus 4.7%; < 0.0001). In postmenopausal women receiving osteoporosis treatment, multiple RFs increased fracture risk. RFs, in addition to bone mineral density, can help identify candidates for osteoporosis treatment

    Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort

    Get PDF
    Subject- and physician-reported data from 4,429 postmenopausal women receiving osteoporosis treatment in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US) were used to assess the prevalence of risk factors (RFs) and on-study fracture. RFs assessed at study entry were age >70 years; fracture since age 50; minimum T-score (hip/spine) ≤−2.5 at diagnosis; body mass index 70 years were the most common RFs in the osteoporosis group, and age >70 years and prior fracture were the most common risk factors in the osteopenia group. Multiple RFs were more common than a single RF in osteoporotic women (54.2% versus 34.6%; P<0.0001) but not osteopenic women (13.8% versus 33.6%; P<0.0001). Women with multiple RFs had more on-study osteoporosis-related fractures than women with a single RF (osteoporosis group: 9.9% versus 6.2%; P=0.0092; osteopenia group: 11.2% versus 4.7%; P<0.0001). In postmenopausal women receiving osteoporosis treatment, multiple RFs increased fracture risk. RFs, in addition to bone mineral density, can help identify candidates for osteoporosis treatment

    Risk of second primary cancer in men with breast cancer

    Get PDF
    INTRODUCTION: A retrospective registry-based cohort study was conducted to examine the risk of second primary cancer following the occurrence of breast cancer in males. METHODS: Data obtained from the California Cancer Registry in the period 1988 to 2003 included 1,926 men aged 85 years and younger diagnosed with a first primary breast cancer. Person-year analysis was applied to determine the risk of second primary cancers after the occurrence of a first primary breast cancer. The effects of age, race, and time since the first breast cancer diagnosis were assessed. RESULTS: Of the 1,926 male breast cancer cases, 221 (11.5%) developed a second primary cancer. Men with first incidence of breast cancer have a significantly higher risk of second cancer (standardized incidence ratio (SIR) = 1.16, 95% confidence interval (CI) = 1.01–1.32). The risk of a second site-specific cancer is elevated for breast cancer (SIR = 52.12, 95% CI = 31.83–80.49), cutaneous melanoma (SIR = 2.98, 95% CI = 1.63–5.00) and stomach cancer (SIR = 2.11, 95% CI = 1.01–3.88). There is a general tendency towards higher risks of second malignancies among younger men compared to older men and the risk increased with the passage of time. CONCLUSION: Male breast cancer patients should be monitored carefully for the occurrence of second primary cancers, especially a second primary breast cancer

    Risk of second primary cancer in men with breast cancer.

    No full text
    corecore